List of ProQR Therapeutics patents

List of ProQR Therapeutics patents

List of PureTech patents

List of Landec Corporation patents

List of Widex patents

Founders educated at Ain Shams University

List of companies in Tesla (company)'s investment portfolio

Patents where

Current Assignee

Name

is

ProQR Therapeutics

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11274300 Oligonucleotide complexes for use in RNA editing	Patent 11274300 was granted and assigned to ProQR Therapeutics on March, 2022 by the United States Patent and Trademark Office.	ProQR Therapeutics	ProQR Therapeutics		United States Patent and Trademark Office	11274300	March 15, 2022
	‌ US Patent 10941402 Chemically modified single-stranded RNA-editing oligonucleotides	Patent 10941402 was granted and assigned to ProQR Therapeutics on March, 2021 by the United States Patent and Trademark Office.	ProQR Therapeutics	ProQR Therapeutics		United States Patent and Trademark Office	10941402	March 9, 2021
	‌ US Patent 10988763 Single-stranded RNA-editing oligonucleotides	Patent 10988763 was granted and assigned to ProQR Therapeutics on April, 2021 by the United States Patent and Trademark Office.	ProQR Therapeutics	ProQR Therapeutics		United States Patent and Trademark Office	10988763	April 27, 2021
	‌ US Patent 11649454 Single-stranded RNA-editing oligonucleotides	Patent 11649454 was granted and assigned to ProQR Therapeutics on May, 2023 by the United States Patent and Trademark Office.	ProQR Therapeutics	ProQR Therapeutics		United States Patent and Trademark Office	11649454	May 16, 2023
	‌ US Patent 10889817 Oligonucleotide therapy for Leber Congenital Amaurosis	Patent 10889817 was granted and assigned to ProQR Therapeutics on January, 2021 by the United States Patent and Trademark Office.	ProQR Therapeutics	ProQR Therapeutics		United States Patent and Trademark Office	10889817	January 12, 2021
	‌ US Patent 10421963 Oligonucleotide therapy for leber congenital amaurosis	Patent 10421963 was granted and assigned to ProQR Therapeutics on September, 2019 by the United States Patent and Trademark Office.	ProQR Therapeutics	ProQR Therapeutics		United States Patent and Trademark Office	10421963	September 24, 2019
	‌ US Patent 11479771 Antisense oligonucleotides for the treatment of eye disease		ProQR Therapeutics	ProQR Therapeutics		United States Patent and Trademark Office	11479771	October 25, 2022
	‌ US Patent 10676737 Targeted RNA editing	Patent 10676737 was granted and assigned to ProQR Therapeutics on June, 2020 by the United States Patent and Trademark Office.	ProQR Therapeutics	ProQR Therapeutics		United States Patent and Trademark Office	10676737	June 9, 2020
	‌ US Patent 10900041 Antisense oligonucleotides for use in treating Alzheimer's disease	Patent 10900041 was granted and assigned to ProQR Therapeutics on January, 2021 by the United States Patent and Trademark Office.	ProQR Therapeutics	ProQR Therapeutics		United States Patent and Trademark Office	10900041	January 26, 2021
	‌ US Patent 9605255 Oligonucleotides for making a change in the sequence of a target RNA molecule present in a living cell	Patent 9605255 was granted and assigned to ProQR Therapeutics on March, 2017 by the United States Patent and Trademark Office.	ProQR Therapeutics	ProQR Therapeutics		United States Patent and Trademark Office	9605255	March 28, 2017
	‌ US Patent 9994856 Method for increasing the activity of a cystic fibrosis transmembrane conductance regulator protein	Patent 9994856 was granted and assigned to ProQR Therapeutics on June, 2018 by the United States Patent and Trademark Office.	ProQR Therapeutics	ProQR Therapeutics		United States Patent and Trademark Office	9994856	June 12, 2018
	‌ US Patent 10612025 Antisense oligonucleotides for the treatment of eye disease	Patent 10612025 was granted and assigned to ProQR Therapeutics on April, 2020 by the United States Patent and Trademark Office.	ProQR Therapeutics	ProQR Therapeutics		United States Patent and Trademark Office	10612025	April 7, 2020
	‌ US Patent 10760076 Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion		ProQR Therapeutics	ProQR Therapeutics		United States Patent and Trademark Office	10760076	September 1, 2020
	‌ US Patent 11781134 Targeted RNA editing	Patent 11781134 was granted and assigned to ProQR Therapeutics on October, 2023 by the United States Patent and Trademark Office.	ProQR Therapeutics	ProQR Therapeutics		United States Patent and Trademark Office	11781134	October 10, 2023
	‌ US Patent 10617707 Oligonucleotides to treat eye disease	Patent 10617707 was granted and assigned to ProQR Therapeutics on April, 2020 by the United States Patent and Trademark Office.	ProQR Therapeutics	ProQR Therapeutics		United States Patent and Trademark Office	10617707	April 14, 2020

15 results

0 selected

15 results

0 selected